Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.61
NSPR's Cash to Debt is ranked lower than
75% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.59 vs. NSPR: 0.61 )
Ranked among companies with meaningful Cash to Debt only.
NSPR' s Cash to Debt Range Over the Past 10 Years
Min: 0.34  Med: 40.90 Max: No Debt
Current: 0.61
Equity to Asset -0.51
NSPR's Equity to Asset is ranked lower than
96% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. NSPR: -0.51 )
Ranked among companies with meaningful Equity to Asset only.
NSPR' s Equity to Asset Range Over the Past 10 Years
Min: -0.65  Med: 0.24 Max: 0.78
Current: -0.51
-0.65
0.78
F-Score: 4
Z-Score: -22.06
M-Score: -1.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -627.06
NSPR's Operating margin (%) is ranked lower than
89% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. NSPR: -627.06 )
Ranked among companies with meaningful Operating margin (%) only.
NSPR' s Operating margin (%) Range Over the Past 10 Years
Min: -840.95  Med: -318.67 Max: -228.66
Current: -627.06
-840.95
-228.66
Net-margin (%) -674.68
NSPR's Net-margin (%) is ranked lower than
89% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. NSPR: -674.68 )
Ranked among companies with meaningful Net-margin (%) only.
NSPR' s Net-margin (%) Range Over the Past 10 Years
Min: -890.53  Med: -464.70 Max: -244.25
Current: -674.68
-890.53
-244.25
ROE (%) -5359.35
NSPR's ROE (%) is ranked lower than
100% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 1.52 vs. NSPR: -5359.35 )
Ranked among companies with meaningful ROE (%) only.
NSPR' s ROE (%) Range Over the Past 10 Years
Min: -521.08  Med: -405.67 Max: -363.41
Current: -5359.35
-521.08
-363.41
ROA (%) -133.70
NSPR's ROA (%) is ranked lower than
93% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: -0.71 vs. NSPR: -133.70 )
Ranked among companies with meaningful ROA (%) only.
NSPR' s ROA (%) Range Over the Past 10 Years
Min: -436.36  Med: -282.07 Max: -155.85
Current: -133.7
-436.36
-155.85
ROC (Joel Greenblatt) (%) -2649.45
NSPR's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. NSPR: -2649.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NSPR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -8439.86  Med: -2853.62 Max: -1484.91
Current: -2649.45
-8439.86
-1484.91
Revenue Growth (3Y)(%) -41.20
NSPR's Revenue Growth (3Y)(%) is ranked lower than
93% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. NSPR: -41.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NSPR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: -41.2
Current: -41.2
EBITDA Growth (3Y)(%) -8.70
NSPR's EBITDA Growth (3Y)(%) is ranked lower than
69% of the 194 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. NSPR: -8.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NSPR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.7  Med: 488.10 Max: 673.3
Current: -8.7
-8.7
673.3
EPS Growth (3Y)(%) -9.40
NSPR's EPS Growth (3Y)(%) is ranked lower than
66% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. NSPR: -9.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NSPR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.4  Med: 431.10 Max: 707.5
Current: -9.4
-9.4
707.5
» NSPR's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

NSPR Guru Trades in

NSPR Guru Trades in

Q3 2015

NSPR Guru Trades in Q3 2015

Jim Simons 525,400 sh (New)
» More
Q4 2015

NSPR Guru Trades in Q4 2015

Jim Simons 100,240 sh (+90.79%)
» More
» Details

Insider Trades

Latest Guru Trades with NSPR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 0.95
NSPR's P/S is ranked higher than
81% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 3.18 vs. NSPR: 0.95 )
Ranked among companies with meaningful P/S only.
NSPR' s P/S Range Over the Past 10 Years
Min: 0.8  Med: 12.20 Max: 98.72
Current: 0.95
0.8
98.72
Current Ratio 1.14
NSPR's Current Ratio is ranked lower than
88% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.86 vs. NSPR: 1.14 )
Ranked among companies with meaningful Current Ratio only.
NSPR' s Current Ratio Range Over the Past 10 Years
Min: 0.13  Med: 2.14 Max: 4.68
Current: 1.14
0.13
4.68
Quick Ratio 0.99
NSPR's Quick Ratio is ranked lower than
80% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. NSPR: 0.99 )
Ranked among companies with meaningful Quick Ratio only.
NSPR' s Quick Ratio Range Over the Past 10 Years
Min: 0.13  Med: 1.80 Max: 4.28
Current: 0.99
0.13
4.28
Days Inventory 188.72
NSPR's Days Inventory is ranked lower than
67% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 136.13 vs. NSPR: 188.72 )
Ranked among companies with meaningful Days Inventory only.
NSPR' s Days Inventory Range Over the Past 10 Years
Min: 127.34  Med: 135.33 Max: 315.56
Current: 188.72
127.34
315.56
Days Sales Outstanding 63.99
NSPR's Days Sales Outstanding is ranked higher than
57% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 70.17 vs. NSPR: 63.99 )
Ranked among companies with meaningful Days Sales Outstanding only.
NSPR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 82.25  Med: 130.26 Max: 138.85
Current: 63.99
82.25
138.85
Days Payable 71.71
NSPR's Days Payable is ranked higher than
55% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 62.81 vs. NSPR: 71.71 )
Ranked among companies with meaningful Days Payable only.
NSPR' s Days Payable Range Over the Past 10 Years
Min: 98.67  Med: 115.77 Max: 132.86
Current: 71.71
98.67
132.86

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.09
NSPR's Price/Median PS Value is ranked higher than
98% of the 246 Companies
in the Global Medical Devices industry.

( Industry Median: 1.04 vs. NSPR: 0.09 )
Ranked among companies with meaningful Price/Median PS Value only.
NSPR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.26  Med: 1.24 Max: 7.44
Current: 0.09
0.26
7.44
Price/Graham Number 0.12
NSPR's Price/Graham Number is ranked higher than
98% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 2.14 vs. NSPR: 0.12 )
Ranked among companies with meaningful Price/Graham Number only.
NSPR' s Price/Graham Number Range Over the Past 10 Years
Min: 0.7  Med: 1.08 Max: 6.18
Current: 0.12
0.7
6.18
Earnings Yield (Greenblatt) (%) -325.35
NSPR's Earnings Yield (Greenblatt) (%) is ranked lower than
98% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. NSPR: -325.35 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NSPR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -567.78  Med: 0.00 Max: 0
Current: -325.35
-567.78
0

More Statistics

Revenue(Mil) $2
EPS $ -2.35
Beta0.17
Short Percentage of Float2.12%
52-Week Range $0.39 - 4.24
Shares Outstanding(Mil)10.73

Analyst Estimate

Dec16
Revenue(Mil)
EPS($) -0.14
EPS without NRI($) -0.14

Business Description

Industry: Medical Devices » Medical Devices
Compare:ASX:RSH, ASX:AMT, NAS:ETRM, TSE:5212, XSAT:ZENI, ASX:GID » details
InspireMD Inc was organized in the State of Delaware on February 29, 2008 as Saguaro Resources, Inc. On March 28, 2011, it effectuated a 1-for-3 forward stock split and changed its name from Saguaro Resources, Inc. to InspireMD, Inc. It is an medical device company focusing on the development and commercialization of its proprietary stent platform technology, MGuard. MGuard provides embolic protection in stenting procedures by placing a micron mesh sleeve over a stent. The Company's initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). According to the TYPHOON STEMI trial and the SOS SVG Trial of patients with acute myocardial infarction and saphenous vein graft coronary interventions, 7.5% to 44% experience adverse cardiac events, including cardiac death, heart attack, and restenting of the artery. When performing stenting procedures in patients with acute coronary symptoms, interventional cardiologists face a difficult dilemma in choosing between bare-metal stents, which have a high rate of restenosis (formation of new blockages), and drug-eluting (drug-coated) stents, which have a high rate of late thrombosis (formation of clots months or years after implantation), require administration of anti-platelet drugs for at least one year post procedure, are more costly than bare-metal stents and have additional side effects. It intends to use its MGuard technology in a broad range of coronary related situations in which complex lesions are required and make it an industry standard for treatment of acute coronary syndromes. It also intends to apply its technology to develop additional products used for other vascular procedures, specifically carotid (the arteries that supply blood to the brain) and peripheral (other arteries) procedures. The Company markets its products through distributers in international markets, mainly in Europe and Latin America.
» More Articles for NSPR

Headlines

Articles On GuruFocus.com
Insiders Roundup: Sales on Facebook Mar 25 2016 
InspireMD Reports 4 Significant Insider Buys Apr 19 2013 

More From Other Websites
INSPIREMD, INC. Files SEC form 8-K, Other Events Apr 19 2016
INSPIREMD, INC. Financials Apr 01 2016
InspireMD Receives Audit Opinion with Going Concern Explanation Apr 01 2016
InspireMD Receives Audit Opinion with Going Concern Explanation Apr 01 2016
UPDATE: InspireMD Receives Audit Opinion With Going Concern Explanation Mar 31 2016
InspireMD Receives Audit Opinion With Going Concern Explanation Mar 31 2016
Dawson James Securities Announces Closing of $1.75 Million Offerings with InspireMD, Inc. Mar 31 2016
INSPIREMD, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 30 2016
InspireMD, Inc. :NSPR-US: Earnings Analysis: Q4, 2015 By the Numbers Mar 29 2016
InspireMD, Inc. :NSPR-US: Earnings Analysis: 2015 By the Numbers Mar 29 2016
INSPIREMD, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers, Financial... Mar 28 2016
InspireMD Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015 Mar 28 2016
InspireMD Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015 Mar 28 2016
INSPIREMD, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events Mar 25 2016
Corporate Insiders Are Backing Up the Truck on Two Battered Healthcare-related Companies and One... Mar 24 2016
InspireMD Announces Closing of Public Offering Mar 22 2016
InspireMD Announces Closing of Private Placement to Certain Officers and Directors Mar 22 2016
INSPIREMD, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events,... Mar 21 2016
InspireMD Announces Closing of Private Placement to Certain Officers and Directors Mar 21 2016
InspireMD Announces Closing of Public Offering Mar 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK